Kawakami, Y., Haas, G.P., Lotze, M.T.: Expansion of Tumor Infiltrating Lymphocytes from Human Tumors 
Using the T cell Growth Factors IL-2 and IL-4. J. Immunotherapy, in press. 
7. Stotter, H., Custer, M.C., Lotze, M.T., et zil.: IL-7 induces human lymphokine activated killer (LAK) cells and 
is regulated by interleukin-4. J. Immunol 146: 150-144, 1991. 
8. Rosenberg, S A., Aebersold, P., Lotze, M.T., et al.: Gene transfer into humans: Immunotherapy of patients with 
advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. 
Med . 323: 570-578, 1990. 
9. Stotter, H. and Lotze, M.T.: Human Lymphokine Activated Killer Activity. Role of IL-2, IL-4, and IL-7. Arch 
Sure 126:1525-30, 1991. 
10. Wong, H. L., Lotze, M.T., Wald, L.M., et al.: Administration of recombinant IL-4 to humans regtdates gene 
expression, phenotype, and function in circulating monocytes. J. Immunol . 148:2118-2125, 1992. 
11. Rubin J. T. and Lotze M.T.: Acute Gastric Mucosal Injury Associated with Systemic Administration of IL-4. 
Surgery 111:274-280, 1991. 
12. Lotze MT. Role of IL-4 in the antitumor response in H. Spits,ed. IL-4 Raven Press, 1992, Chapter 15, 237-262. 
13. Lotze MT. Trials and Tribulations: The Cost of Developing Gene Therapies FASEB J1 5:3013-3014, 1991. 
14. Lotze MT. Clinical Protocol: The treatment of patients with melanoma using IL-2, IL-4, and tumor infdtrating 
lymphocytes. Human Gene Therapy. 3: 167-177, 1992. 
15. Lotze MT, Zeh HJ, Elder EM, et al.: Use of T-cell Growth Factors (IL-2 to IL-12) in the investigation and 
treatment of melanoma. J. Immunotherapy . 12: 212-217, 1992 
16. Weidmann E, Elder EM, Lotze, MT., et al.: Usage of the T-Cell receptor Vp chain genes in fresh and cultured 
tumor-infdtrating lymphocytes from human melanoma. Int. J. Cancer 54:383-390, 1993. 
17. Tahaua H, Mueller GM, Ricordi C, Robbins PD, Lotze MT. Islet cell transplantation facilitated by gene transfer. 
Transplant. Proc. 24:2975-2976, 1992. 
18. Wong HL, Costa GL, Lotze MT., et al.: IL-4 differentially regulates monocyte IL-1 family gene expression and 
synthesis m vitro and in vivo . J Exp Med . 177:775-781, 1993. 
Sanda MG, Yang JC, Lotze MT., et al.: Intravenous administration of recombinant human macrophage colony- 
stimulating factor to patients with metastatic cancer: A Phase I Study. J Clin One. 10: 1643-1649, 1992. 
20. Robbins PD, Tahara H, Lotze MT., et al.: Retroviral Vectors for use in Human Gene Therapy for Cancer, 
Gaucher Disease, and Arthritis. Annals of the New York Acad. Sci. . in press. 
21. 2^h HJ, Hurd S, Lotze MT., et al.: IL-12 Promotes the Proliferation and Cytolytic Maturation of Immune 
Effectors: Implications for the Immunotherapy of Cancer. J Immunotherapy , in press, 1993. 
22. Zeh HJ, Tahara H, and Lotze MT. Interleukin- 12. Cytokine Handbook . Editor, A. Thomson, 1994. 
23. Nastala C, Edington HD, Lotze MT., et al.: Recombinant IL-12 (r-mIL-12) Mediates Regression of Both 
Subcutaneous and Metastatic Murine Tumors. Surgical Forum. 44:518-521, 1993. 
24. Edington H, McKinney TG, Lotze MT., et al.: Recombinant IL-12 Induces Tumor Regression in Murine 
Models: Interferon-Gamma But Not Nitric Oxide Dependent Effects. Submitted, 1993. 
25. Tahara H, Pappo I, Lotze MT., et al.: Fibroblasts Genetically Engineered to Secrete IL-12 can Suppress 
Tumor Growth In Vivo and Induce Antitumor Immunity To A Murine Melanoma. Submitted 
26. Lotze MT. Transplantation and Adoptive Cellular Therapy of Cancer: The Role of T cell Growth Factors. 
Cell Transplantation. 2:33-47, 1993. 
27. Storkus W. J., Salter R. D., Lotze, M.T., et al.: Identification of T cell epitopes: Rapid isolation of class I- 
presented peptides from viable cells by mild acid elution. J. Immunother.. in press, 1993. 
28. Storkus W. J., Zeh III, H. J., Lotze, M.T., et al.: Isolation of human melanoma peptides recognized by class I 
restricted tumor infiltrating T lymphocytes. J. Immunol. , in press, 1993. 
29. Marincola FM, Rubin JT, Lotze MT., et al.: HLA association with response and toxicity in melanoma padenis 
treated with LL-2 based immunotherapy. Cancer Research 52:6561-6, 1992. 
30. White MV, Igarashi Y, Lotze MT., et al.: Effects of invivo administration of IL-2 and IL-4 alone and in 
combination, on ex vivo human basophil histamine release. Blood 79:1491-5, 1992. 
31. Lotze MT, Finn OJ. Cellular immunity and the immunotherapy of cancer. J. Immunotherapy. 14:79-87, 1993. 
32. Hunt, JD, Landreneau RJ, Lotze MT., et al.: Transfer and expression of the human IL-4 gene in carcinoma and 
stromal cell strziins derived from liing cancer patients. J Immunotherapy, in press. 
Lotze MT, Yang JC, Topalian SL, et al.: Prospective randomized trial of high-dose IL-2 alone or in conjunction 
with LAK cells for the treatment of patients with advanced cancer. Jl. Nat. Cancer Inst. 85:622-32, 1993. 
Recombinant DNA Research, Volume 19 
[6711 
